Objective
To evaluate the utility of ultrasound surveillance in obese women.
Study Design
Retrospective cohort of all obese women undergoing sonography at a single center from 2005–2013. Inclusion criteria were: body mass index ≥30 kg/m2, singleton, ≥1 ultrasound performed <20 weeks, and ≥1 ultrasound performed ≥24 weeks. Pregnancies with medical complications, fetal anomalies or preterm premature rupture of membranes were excluded. Outcomes considered were small for gestational age (SGA), large for gestational age (LGA), macrosomia, oligohydramnios, and polyhydramnios. We calculated the number needed to screen (NNS) and 95% confidence intervals (CI) for scans performed during 3 gestational age ranges (240/7-316/7, 320/7-356/7, and ≥360/7 weeks).
Results
2,002 sonograms were performed in 1,164 obese women ≥24 weeks. SGA was diagnosed in 59 (5.1%) pregnancies; 7 (0.6%) were diagnosed <32 weeks (NNS 159 (95% CI 69–490). LGA was diagnosed in 38 (3.3%) cases; only 1 was identified <32 weeks and was not LGA at birth. For every 29 (95% CI 19–46) scans performed >36 weeks, 1 case of macrosomia was identified. Amniotic fluid abnormalities were diagnosed in 44 (3.8%) pregnancies (oligohydramnios n=19, polyhydramnios n=25); 34.1% were diagnosed <32 weeks (NNS 113, 95% CI 55–282 for oligohydramnios, NNS 100, 95% CI 50–230 for polyhydramnios). At ≥36 weeks, 7 (95% CI 6–8) scans were needed to diagnose any fluid or growth abnormality.
Conclusion
In obese women without co-morbidities, few sonographic diagnoses of amniotic fluid or fetal growth abnormalities are made <32 weeks gestational age. Therefore, if a policy of serial sonographic surveillance is utilized, we suggest ultrasounds for fluid and growth in obese women begin ≥32 weeks.